Roche, a Swiss drugmaker, accelerates obesity drug development, aiming for market entry by 2028.
Roche, a Swiss drugmaker, plans to speed up the development of its anti-obesity drugs to compete with rivals like Eli Lilly and Novo Nordisk, according to the Financial Times. Roche CEO Thomas Schinecker stated that their first obesity drugs may come to market by 2028, significantly faster than expected. The company has an experimental once-daily pill candidate with positive results in an early-stage trial.
July 29, 2024
3 Articles